REG - Poolbeg Pharma PLC - RSV AI Drug Candidate Analysis Update

Poolbeg PharmaAnnouncement

20/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231220:nRST3715Xa&default-theme=true

RNS Number : 3715X  Poolbeg Pharma PLC  20 December 2023

Poolbeg Pharma plc

 

Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified
Using AI

RSV drug candidates with the highest probability of success prioritised

 

20 December 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces the positive
outputs from the lab-based analysis and successful prioritisation of the
Respiratory Syncytial Virus ('RSV') drug targets and treatments identified
(https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/rnlvnkw)
as part of its artificial intelligence ('AI') led programme.

 

Poolbeg's team of scientific experts have reviewed the comprehensive data
package obtained from this lab-based analysis and has strategically
prioritised a select number of the RSV drug candidates that were analysed. The
Company is actively exploring the most effective way to progress the
prioritised drug candidates in order to generate value. Poolbeg believes the
data obtained reflects the high potential of this AI-led programme and
supports its partnering efforts.

 

The global interest in AI-led drug discovery continues to grow, with major
pharmaceutical players making substantial investments in the field. Poolbeg's
RSV AI programme identified these drug treatment candidates in just 10 months.
AI-led drug discovery can accelerate the timeline achievable which reduces
costs while also decreasing risks and providing a higher likelihood of success
in bringing groundbreaking therapies to patients.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented:
"The positive outputs from this analysis, and the successful prioritisation of
our RSV drug candidates, is a testament to the power of our AI-led drug
discovery programme. As we engage in partnering discussions, these results
position Poolbeg as a key player in the evolving landscape of AI-driven drug
discovery."

 

- Ends -

 

Enquiries

 

 Poolbeg Pharma Plc                                                      +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)        +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                    +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                                 +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                        +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                                 poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need. Its
model focusses upon developing its exciting clinical assets and
commercialising approved and marketed drugs to fund the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

Poolbeg's clinical programmes target large addressable markets including CRS
induced by cancer immunotherapies, infectious disease, and metabolic
conditions such as obesity with the development of an oral GLP-1R agonist. It
uses a cost-effective development philosophy to generate high quality human
data to support partnering and further development. Its AI-led infectious
disease programmes analyse unique data from human challenge trials to identify
clinically relevant drug targets and treatments, leading to faster development
and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

About RSV

Respiratory Syncytial Virus (RSV) which inflames the smallest airways of the
lungs, sends an average of 58,000-80,000 children under the age of five to
hospital each year in the US alone, according to the US Centers for Disease
Control and Prevention (CDC). RSV can also be dangerous for adults over the
age of 65, resulting in around 177,000 hospitalisations per year in the
United States alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBRBDDLSBDGXC